BioNTech Investor Day Presentation Deck

BNT311 Combining checkpoint blockade and conditional T cell co-stimulation Dual targeted 4-1BB co-stimulation that is conditional on PD-L1 binding GEN1046 (BNT311) Conditional 4-1BB agonist activity BNT311 binding affinity: KD PD-L1: 0.16 nmol/L, 4-1BB: 0.15 nmol/L 4-1BB-expressing cell (eg, T cell) 4-1BB GEN1046 PD-1 Checkpoint blockade PD-L1 PD-L1-expressing cell (eg, tumor cell) PD-1/PD-L1 blockade (fold increase) 8 + N 0 GEN1046 → Anti-PD-L1 mAb Atezolizumab analogue Isotype ctrl * BNT311 (Gen1046) is partnered with Genmab based on 50/50 sharing of costs and profits. 1 Muik A, et al. Cancer Discov 2022; 12:1248-1345. TITIE 0.001 0.01 0.1 1 10 Antibody concentration (µg/mL) 100 Enhanced NK cell activity Novel mechanism that enhances T- and NK-cell function Enhanced recruitment of immune cells NK coll Reactivation of exhausted T cells Tumor Tumor lysin Activated T cell PD-1 Flictivated PD-1 high cell GEN1046 Blood vessel Tumor 4-1BB Infiltrating immune cells PD-L1 Blood vesse Activated T cell Tumor Jysis Y Dendred Tumor-draining lymph node Differentiation Granzyme Perforin Semen T cell Enhanced effector T-cell activity Activated T cell Proliferation Enhanced T-cell activation Cytokines Protein therapeutics Activate T cell Chemokines T-cell proliferation and differentiation Conditional bi-specific molecule for two preclinically validated targets: PD-L1: receptor-ligand expressed on tumor cells to inhibits the proliferation of PD1-positive cells, and participates in the immune evasion 4-1BB: costimulatory tumor necrosis factor expressed on T cells and NK-cells. Activating the 4-1BB pathway enhances T cell proliferation, T cell effector functions, and prevents T cell death BIONTECH 116

View entire presentation